RBC Capital raised the firm’s price target on BioCryst (BCRX) to $15 from $14 and keeps an Outperform rating on the shares. Following the announced transaction to acquire Astria Therapeutics (ATXS), their conference call discussing terms, and the firm’s discussion with BioCryst’s management team, RBC has further conviction that despite the near-term dilution tradeoff, this is a very sound deal that should leverage BioCryst’s core competencies well, and set up their franchise even better. The firm added that Tuesday’s weakness in BioCryst shares presents a compelling buying opportunity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst’s Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability
- BioCryst’s Strategic Acquisition of Astria Therapeutics Boosts Market Position and Financial Outlook
- BioCryst price target raised to $15 from $14 at Jefferies
- Astria Therapeutics downgraded to Hold from Buy at Jefferies
- Midday Fly By: Big banks report beats, GM takes $1.6B EV charge